Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Ipratropium bromide, Xylometazoline hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Ipratropium bromide, Xylometazoline hydrochloride
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for 2. What you need to know before you use Otrivine Extra Dual Relief Nasal spray 3. How to use Otrivine Extra Dual Relief Nasal spray 4. Possible side effects 5. How to store Otrivine Extra Dual Relief Nasal spray 6. Contents of the pack and other information

1. WHAT OTRIVINE EXTRA DUAL RELIEF NASAL SPRAY IS AND WHAT IT IS USED FOR Otrivine Extra Dual Relief Nasal spray is a combination medicinal product consisting of two different substances (xylometazoline hydrochloride and ipratropium bromide). One of the active ingredients (ipratropium bromide) helps with the runny nose, the other (xylometazoline hydrochloride) has a decongesting effect. Otrivine Extra Dual Relief Nasal spray is used for the treatment of nasal congestion with runny nose (rhinorrhea) in connection with common colds.

What you need to know before you take it

E OTRIVINE EXTRA DUAL RELIEF NASAL SPRAY Do not use Otrivine Extra Dual Relief Nasal spray

  • In children below 18 years of age, as adequate information on safety and efficacy is not available
  • If you are allergic to xylometazoline hydrochloride or ipratropium bromide or any of the other ingredients of this medicine (listed in section 6)
  • If you are allergic to atropine or atropine like substances such as hyoscyamine and scopolamine
  • If you had your pituitary gland removed by surgery carried out through the nose
  • If you have had brain surgery where the operation was carried out through the nose or mouth
  • If you suffer from glaucoma (increased pressure in the eye)
  • If you have a very dry nose (inflammatory nasal dryness, rhinitis sicca or atrophic rhinitis). Warnings and precautions Otrivine Extra Dual Relief Nasal spray may give you sleep disturbances, dizziness, tremor, irregular heart rhythm or elevated blood pressure in very sensitive patients. Consult your doctor if these symptoms occur and are bothersome. Talk to your doctor or pharmacist before using Otrivine Extra Dual Relief Nasal spray if you suffer from:
  • Heart disease (e.g. long QT syndrome)
  • Raised blood pressure
  • Diabetes
  • An overactive thyroid gland (hyperthyroidism)
  • Difficulty in urinating and/or an enlarged prostate gland
  • Narrow-angle glaucoma (sudden build-up of pressure in the eye)
  • A tendency to have nosebleeds
  • Obstruction of the intestine (paralytic ileus)
  • Cystic fibrosis
  • Benign tumour of the adrenal gland that produces high amounts of adrenaline and nor-adrenaline (phaeochromocytoma) or a particular sensitivity to adrenaline and nor-adrenaline Immediate hypersensitivity (allergic reaction) may occur in rare cases. This may be seen as itchy red rash with raised inflammation of the skin (hives), difficulty breathing or speaking, difficulty swallowing due to swelling of the lips, face or throat. These symptoms may appear individually or all combined as a severe allergic reaction. If this occurs, immediately STOP using this medicine (see section 4). Prolonged or excessive use may cause stuffiness in the nose to return or worsen and swelling of the nasal mucosa. Children, adolescents and elderly Otrivine Extra Dual Relief Nasal spray is not recommended for use in children and adolescents below 18 years or in the elderly above 70 years of age, as adequate information on safety and efficacy is not available.

Other medicines and Otrivine Extra Dual Relief Nasal spray Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. It is particularly important that you mention the following:

  • Monoamine oxidase inhibitors (used for treatment of depression). If you are taking or have taken these medicines in the last two weeks, dangerous rises of the blood pressure may occur
  • Tri-cyclic and tetra-cyclic antidepressants. If you are taking or have taken these medicines in the last two weeks, dangerous rises of the blood pressure may occur
  • Medicines used for travel sickness (medicines containing anticholinergic substances)
  • Medicines used for gut disorders (particularly those for abnormal motility) (medicines containing anticholinergic substances)
  • Medicines used for the treatment of breathing disorders (Beta 2-agonists) such as asthma or chronic obstructive pulmonary disease (COPD) as it may worsen your glaucoma if you have a history of angle closure glaucoma If you use any of the above medicines, consult a doctor before using Otrivine Extra Dual Relief Nasal spray. Pregnancy and breast-feeding Otrivine Extra Dual Relief Nasal spray should not be used during pregnancy unless your doctor recommends it. During breast-feeding Otrivine Extra Dual Relief Nasal spray should not be used unless your doctor decides the advantages outweigh the potential risks to the infant. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines: Visual disturbances (including blurred vision and dilation of the pupil), dizziness and fatigue have been reported with Otrivine Extra Dual Relief Nasal spray. If affected, you should avoid driving, operating machinery or taking part in activities where these symptoms may put yourself or others at risk.

How to take it

OTRIVINE EXTRA DUAL RELIEF NASAL SPRAY Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is: Adults: One puff in each nostril as needed, up to 3 times daily for maximum 7 days. Leave at least 6 hours between two doses. Do not exceed 3 applications daily into each nostril. Do not exceed the stated dose. Use the smallest dose you need to treat your symptoms and use it for the shortest time needed to achieve desired effect. Duration of treatment: Do not use this medicine for more than 7 days. It is recommended that you stop treatment with Otrivine Extra Dual Relief Nasal spray as soon as your symptoms improve, even if this is sooner than 7 days, in order to minimise the risk of adverse reactions. If symptoms get worse or do not improve after 7 days, consult a doctor. If you think the effect of this medicine is too strong or too weak, consult your doctor or pharmacist. Instructions for use:

  • Remove the cap. Before first use

Prime the pump by pumping 5 times. Once primed the pump will normally remain charged throughout regular daily treatment periods. 1. Clear your nose. 2. Hold the bottle upright with thumb on the actuation button. 3. For a no dripping effect, stay upright and insert the nozzle into the nostril. 4. Press on the button to spray and breathe in gently through the nose at the same time. Repeat this procedure (Steps 2 to 4) in the other nostril. 5. After each use, clean and dry the nozzle. 6. Put the protective cap back on until an audible "click" is heard.

1. Clear nose

2. Thumb on button

3. Insert in nose

4. Press button

5. Clean and dry

6. Replace cap

The effect occurs within 5-15 minutes. Should the spray not be ejected during the full actuation stroke, or if the product has not been used for longer than 7 days, the pump will need to be re-primed with 2 pumps. If the full spray is not administered, the dose should not be repeated. To avoid possible spread of infection, the spray should only be used by one person. Avoid spraying Otrivine Extra Dual Relief Nasal spray in or around the eyes. If this happens thoroughly rinse the eyes with cold water. Your vision may become temporarily blurred and the eye irritated, painful and red. If this happens contact your doctor for advice. Worsening of narrow angle glaucoma may also occur. If you use more Otrivine Extra Dual Relief Nasal spray than you should: If you, or someone else, have taken more medicine than you should, contact your doctor, hospital or emergency room for assessment of the risk. It is advisable to take this leaflet, bottle or pack with you. This is particularly important for children who are more likely to develop adverse events than adults. Symptoms of overdose are severe dizziness, sweating, severely lowered body temperature, headache, slow heartbeat, rapid heartbeat, impaired breathing, coma, convulsion, hypertension (high blood pressure) which may be followed by hypotension (low blood pressure). Other symptoms may be dry mouth, difficulties focusing with the eyes and hallucinations. If you forget to use Otrivine Extra Dual Relief Nasal spray Do not take a double dose to make up a forgotten one. MOCK UP

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. STOP using Otrivine Extra Dual Relief Nasal spray and seek medical help immediately if you have any of the following:

  • Palpitations and increased heart rate (affects less than 1 in 100 people)
  • Signs of an allergic reaction as difficulty breathing, speaking or swallowing; swelling of the face, lips, tongue or throat; severe itching of the skin, with a red rash or raised bumps (frequency not known cannot be estimated from available data)
  • Disturbances of vision (including blurred vision, worsening of glaucoma or increased pressure in the eye), rainbow-coloured circles/haloes around bright lights and/or eye pain (frequency not known cannot be estimated from available data). The most common side effects are nose bleeding and nasal dryness. Many of the side effects reported are also symptoms of common cold. Very common side effects (may affect more than 1 in 10 people):
  • Nose bleeding Common side effects (may affect up to 1 in 10 people):
  • Nasal discomfort, congestion of the nose, dry nose, pain in the nose
  • Dry mouth, dry or irritated throat
  • Altered taste sensation, headache, dizziness, local burning sensation
  • Nausea Uncommon (may affect up to 1 in 100 people):
  • Nasal ulcer, sneezing, pain in the throat, cough, hoarseness
  • Stomach upsets
  • Altered smell sensation, shakiness
  • Discomfort, tiredness
  • Sleeplessness
  • Irritation of the eyes, dry eyes, swelling of the eyes, redness of the eyes
  • Palpitations, increased heart rate Rare (may affect up to 1 in 1,000 people):
  • Runny nose Very Rare (may affect up to 1 in 10,000 people):
  • Reaction to the medicine such as swelling, rash, itching
  • Visual impairment Frequency not known (cannot be estimated from available data):
  • Hives
  • Discomfort around the nose
  • Difficulty swallowing, sudden spasm of throat muscle, swelling of throat
  • Discomfort in the chest, thirst
  • Irregular heart rhythm
  • Difficulties focusing with the eyes, dilation of the pupils, flashing lights, increased eye pressure, glaucoma, blurred vision, haloes around bright lights and eye pain
  • Difficulties emptying the bladder In order to minimise the risk of side effects, it is recommended that you stop treatment with Otrivine Extra Dual Relief Nasal spray as soon as your symptoms improve. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. UK: You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

Otrivine Extra Dual Relief Nasal spray is available as a 10 ml nasal spray with a thumb laterally actuated metered-dose spray pump with protective cap. Market Authorisation Holder Haleon Ireland Dungarvan Limited, Knockbrack, Dungarvan, County Waterford, Ireland. Manufacturer Haleon Germany GmbH, Barthstraße4, 80339 München, Germany or Haleon UK Trading Services Limited, Weybridge, KT13 0NY, U.K This medicinal product is authorised in the Member States of the EEA under the following names: AT

Otrivin Duo 0,5 mg/ml + 0,6 mg/ml Nasenspray, Lösung

BE

Otrivine Duo 0,5mg/ml + 0,6mg/ml solution pour pulvérisation nasale

CY

Otrivin Advance (0,5mg/ml + 0,6mg/ml) nasal spray solution

CZ

Otrivin Duo

DK

Otrivin Comp næsespray, opløsning

EE

Otrivin Total

EL

Otrivin Advance 0,5mg/ml + 0,6mg/ml Ρινικό εκνέφωμα, διάλυμα

ES

Rhinovín Duo 0,5 mg/ml + 0,6 mg/ml solución para pulverización nasal

FI

Otrivin Comp 0,5mg/ml + 0,6mg/ml nenäsumute, liuos

HU

Otrivin Komplex 0,5mg/ml + 0,6mg/ml oldatos orrspray

IE

Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml Nasal Spray

IS

Otrivin Comp 0,5mg/ml + 0,6mg/ml nefúði lausn

IT

RINAZINA DOPPIA AZIONE 0,5 mg/ml + 0,6 mg/ml spray nasale, soluzione

LT

OtriDuo 0,5 mg/0,6 mg/ml nosies purškalas, tirpalas

LU

Otrivine Duo 0,5mg/ml + 0,6mg/ml solution pour pulvérisation nasale

LV

Otrivin Total 0,5 mg/ml + 0,6 mg/ml deguna aerosols, šķīdums

MT

Otrivine Extra Dual Relief 0.5mg/ml + 0.6mg/ml Nasal Spray

NL

Otrivin Duo Xylometazoline hydrochloride & Ipratropium bromide, 0,5/0,6 mg/ml, neusspray, oplossing

NO

Otrivin Comp 0,5mg/ml + 0,6mg/ml nesespray, oppløsning

PL

Otrivin Ipra MAX

PT

Vibrocil ActilongDuo 0.5mg/ml + 0.6mg/ml soluçao para pulverizaçao nasal

RO

Vibrocil Duo 0,5mg/ml + 0,6mg/ml spray nazal, solutie

SE

Otrivin Comp 0,5mg/ml + 0,6 mg/ml nässpray lösning

SI

Otrivin Duo 0,5 mg/0,6 mg v 1 ml pršilo za nos, raztopina

SK

Otrivin Duo

UK (NI)

Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml Nasal Spray

This leaflet was last revised in July 2025 Trade Marks are owned by or licensed to the Haleon group of companies.

How to store it

OTRIVINE EXTRA DUAL RELIEF NASAL SPRAY Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month. This date applies even if the packaging has been opened. Do not store above 25°C. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What Otrivine Extra Dual Relief Nasal spray contains The active substances are xylometazoline hydrochloride and ipratropium bromide. 1 ml contains 0.5 mg xylometazoline hydrochloride and 0.6 mg ipratropium bromide. 1 puff contains 70 micrograms xylometazoline hydrochloride and 84 micrograms ipratropium bromide. The other ingredients are disodium edetate, glycerol (85%), purified water, sodium hydroxide and hydrochloric acid. What Otrivine Extra Dual Relief Nasal spray looks like and contents of the pack Otrivine Extra Dual Relief Nasal spray is a clear solution. The bottle contains approximately 70 puffs.

MOCK UP

Frequently asked questions about Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution

How do I take Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution?

Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution comes as nasal spray containing 0.5mg/ml / 0.6mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution?

The active substance in Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution is ipratropium bromide, xylometazoline hydrochloride.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

  • Source: electronic medicines compendium (emc), Datapharm
  • Active substance: ipratropium bromide, xylometazoline hydrochloride
  • Official document: view the original leaflet on emc →
Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Ipratropium bromide (4 medicines), Ipratropium bromide, xylometazoline hydrochloride (1 medicine), Xylometazoline hydrochloride (11 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Symptomatic treatment of nasal congestion and rhinorrhea in connection with common colds.

4.2. Posology and method of administration

Posology

Adults: 1 puff in each nostril up to 3 times daily. At least 6 hours should elapse between two doses. Do not exceed 3 applications daily into each nostril.

The treatment duration should not exceed 7 days (see section 4.4).

Do not exceed the stated dose. The lowest dose necessary to achieve efficacy should be used for the shortest duration of treatment.

It is recommended to stop treatment, when the symptoms have diminished, even before the maximum duration of treatment of 7 days, in order to minimize the risk of adverse reactions (see section 4.8).

Paediatric population

Otrivine Extra Dual Relief is not recommended for use in children and adolescents below 18 years of age due to lack of sufficient documentation.

Geriatrics

There is only limited experience of use in patients above 70 years of age.

Method of administration

Vertically actuated pump:

Before the first application, prime the pump by actuating 4 times. Once primed the pump will normally remain charged throughout regular daily treatment periods.

1. Clear the nose.

2. Hold the bottle upright with thumb under base and nozzle between two fingers.

3. Lean forward slightly and insert the nozzle into a nostril.

4. Spray and breathe in gently through the nose at the same time.

5. Repeat this procedure in the other nostril.

6. Clean and dry the nozzle before replacing back the cap right after use.

Should the spray not be ejected during the full actuation stroke, or if the product has not been used for longer than 6 days, the pump will need to be reprimed with 4 actuations as initially performed. If the full spray is not administered, the dose should not be repeated.

Thumb laterally actuated pump:

Before the first use

Prime the pump by actuating 5 times. Once primed the pump will normally remain charged throughout regular daily treatment periods.

Remove the cap.

1. Clear the nose.

2. Hold the bottle upright with thumb on the actuation button.

3. For a no dripping effect, stay upright and insert the nozzle into a nostril.

4. Press on the button to spray and breath in gently through the nose at the same time.

Repeat this procedure (step 2 to 4) in the other nostril.

5. After each use, clean and dry the nozzle.

6. Put the protective cap back on until an audible “click” is heard.

Should the spray not be ejected during the full actuation stroke, or if the product has not been used for longer than 7 days, the pump will need to be re-primed with 2 actuations.

If the full spray is not administered, the dose should not be repeated.

To avoid possible spread of infection, the spray should only be used by one person.

Be careful not to spray in the eyes.

4.3. Contraindications

Otrivine Extra Dual Relief should not be given to children under the age of 18 due to lack of sufficient documentation.

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Hypersensitivity to atropine or atropine like substances such as, hyoscyamine and scopolamine.

After surgical operations where dura mater may have been penetrated, e.g. trans-sphenoidal hypophysectomy or other trans-nasal operations.

Glaucoma.

Rhinitis sicca or atrophic rhinitis.

4.4. Special warnings and precautions for use

The medicinal product must be used with caution in patients who are sensitive to adrenergic substances, which may give symptoms such as sleeping disturbances, dizziness, tremor, cardiac arrythmias or elevated blood pressure.

The medicinal product must be administered with caution to patients with:

- hypertension, cardiovascular diseases. Patients with long QT syndrome treated with xylometazoline may be at increased risk of serious ventricular arrhythmias

- hyperthyroidism, diabetes mellitus

- hypertrophy of the prostate, stenosis of the bladder bar

- pheochromocytoma

- cystic fibrosis

- monoamine oxidase inhibitor (MAOI) treatment or who have received them in the last two weeks (see section 4.5 Interactions)

- Tri and tetra-cyclic antidepressants treatment or who have received them in the last two weeks (see section 4.5 Interactions)

- Beta 2-agonists treatment (see section 4.5 Interactions)

Caution is recommended in patients predisposed to:

- angle closure glaucoma

- epistaxis (e.g. elderly)

- paralytic ileus

Immediate hypersensitivity including urticaria, angioedema, rash, bronchospasm, pharyngeal oedema and anaphylaxis may occur.

The treatment duration should not exceed 7 days, as chronic treatment with xylometazoline hydrochloride may cause swelling of the nasal mucosa and hypersecretion because of increased sensibility in the cells, “rebound effect” (rhinitis medicamentosa).

Patients should be instructed to avoid spraying Otrivine Extra Dual Relief in or around the eye. If Otrivine Extra Dual Relief gets in contact with the eyes, the following may occur: temporary blurred vision, irritation, pain, red eyes. Aggravation of angle closure glaucoma may also develop.

The patient should be instructed to rinse their eyes with cold water if Otrivine Extra Dual Relief gets in direct contact with the eyes and to contact a doctor if they experience pain in the eyes or blurred vision.

Keep out of the sight and reach of children.

4.5. Interaction with other medicinal products and other forms of interaction

Monoaminoxidase inhibitors (MAO inhibitors) or tri- and tetra-cyclic antidepressants

Concomitant use or use within the last 2 weeks of sympathomimetic preparations may induce severely elevated blood pressure and is therefore not recommended. Sympathomimetic preparations release catecholamine, which results in a major release of noradrenaline which in turn has a vasoconstrictive effect resulting in elevated blood pressure. In critical cases of elevated blood pressure, treatment with Otrivine Extra Dual Relief should be discontinued and the elevated blood pressure treated. (see section 4.4 Warnings and Precautions)

Beta 2-agonists

Concomitant use with ipratropium may cause an increased risk of acute glaucoma in patients with a history of angle closure glaucoma.

There have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, narrow-angle glaucoma and eye pain) when aerosolised ipratropium bromide either alone or in combination with an adrenergic beta 2-agonist, has come into contact with the eyes. (see section 4.4 Warnings and Precautions)

Concomitant administration of other anticholinergic drugs may enhance the anticholinergic effect.

The above interactions have been studied individually for both of the active substances of Otrivine Extra Dual Relief, not in combination.

No formal interaction studies with other substances have been performed.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are insufficient data on the use of this product in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see Non-clinical information). It is advisable not to take this product during pregnancy.

Xylometazoline

The available data indicate the potential for xylometazoline to exert a systemic vasoconstrictor effect. In view of its systemic vasoconstrictor effect, it is advisable not to take xylometazoline during pregnancy.

Ipratropium

The clinical safety ipratropium bromide during human pregnancy has not been established. Non-clinic data have demonstrated embryotoxicity following administration of ipratropium bromide to rabbits via inhalation at doses greater than the clinical dose (see Non-clinical information).

Breast-feeding

There are insufficient data to determine if this product is excreted in human breast milk. This product should only be used while breast feeding under medical advice. If the expected benefit to the mother is greater than possible risk to the infant, the lowest effective dose and the duration of treatment should be considered.

Xylometazoline

There is no evidence of any adverse effect on the breast-fed infant. It is unknown if xylometazoline is excreted in breast milk.

Ipratropium

It is not known whether ipratropium bromide is excreted in breast milk.

Fertility

There are insufficient data on the impact of this product on fertility.

Xylometazoline

There are no adequate data for the effects of xylometazoline hydrochloride on fertility and no animal studies are available.

Ipratropium

Non-clinical data have demonstrated no evidence of impaired fertility following oral administration of ipratropium bromide to rats at doses greater than the clinical dose (see Preclinical safety data).

4.7. Effects on ability to drive and use machines

Visual disturbances (including blurred vision and mydriasis), dizziness and fatigue have been reported with Otrivine Extra Dual Relief. Patients should be advised that if affected they should not drive, operate machinery or take part in activities where these symptoms may put themselves or others at risk.

4.8. Undesirable effects

Summary of the safety profile

The most commonly reported adverse reactions are epistaxis occurring in 14.8% and nasal dryness occurring in 11.3% of patients.

Many of the adverse events reported are also symptoms of common cold.

Tabulated list of adverse reactions

The adverse reactions are presented by system organ class and frequency. Frequencies are defined as:

Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1000 and <1/100); Rare (≥1/10000 and <1/1000); Very rare (< 1/10,000); Not known (can not be estimated from the available data)

Xylometazoline and Ipratropium

The following adverse reactions for the combination of xylometazoline and ipratropium were reported in two randomised clinical studies and one non-interventional post-marketing study with the product as well as from post-marketing surveillance.

MeDRA SOC

Adverse Reactions

Frequency

Immune system disorders

Hypersensitivity reaction (angioedema, rash, pruritis)

Very rare

Psychiatric disorders

Insomnia

Uncommon

Nervous system disorders

Dysgeusia

Common

Parosmia, Tremor

Uncommon

Eye disorders

Eye irritation, dry eye

Uncommon

Photopsia

Not known

Cardiac disorders

Palpitations, tachycardia

Uncommon

Respiratory, thoracic and mediastinal disorders

Epistaxis

Very common

Nasal congestion, rhinalgia

Common

Nasal ulcer, dysphonia, oropharyngeal pain, sneezing

Uncommon

Rhinorrhea

Rare

Paranasal sinus discomfort

Not known

Gastrointestinal disorder

Dyspepsia

Uncommon

Dysphagia

Not known

General disorders and administration site conditions

Fatigue, discomfort

Uncommon

Chest discomfort, thirst

Not Known

Xylometazoline

The following adverse reactions have been reported in clinical trials and post-marketing surveillance with xylometazoline.

MeDRA SOC

Adverse Reactions

Frequency

Nervous system disorders

Headache

Common

Eye disorders

Visual impairment

Very rare

Respiratory, thoracic and mediastinal disorders

Nasal dryness, nasal discomfort

Common

Epistaxis

Uncommon

Gastrointestinal disorders

Nausea

Common

General disorders and administration site conditions

Application site burn

Common

Ipratropium bromide

The following adverse reactions were identified from data obtained in clinical trials and pharmacovigilance during post approval use of the drug.

MeDRA SOC

Adverse Reactions

Frequency

Immune system disorders

Anaphylactic reaction, hypersensitivity

Not known

Nervous system disorders

Dizziness, headache

Common

Eye disorders

Corneal oedema, conjunctival hyperaemia

Uncommon

Glaucoma, intraocular pressure increased, accommodation disorder, blurred vision, halo vision, mydriasis, eye pain

Not known

Cardiac disorders

Supraventricular tachycardia, palpitations

Uncommon

Atrial fibrillation

Not known

Respiratory, thoracic and mediastinal disorders

Throat irritation, dry throat

Common

Cough

Uncommon

Laryngospasm, pharyngeal oedema

Not known

Gastrointestinal disorders

Dry mouth

Common

Nausea

Uncommon

Skin and subcutaneous tissue disorders

Rash, urticaria pruritis

Not known

Renal and urinary disorders

Urinary retention

Not Known

Description of selected adverse reactions

Several of the adverse reactions listed under “Not known” have only been reported once for the product in clinical trials or are reported from postmarketing surveillance only, thus an estimate of the frequency based on the present number of patient treated with Otrivine Extra Dual Relief cannot be given.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

4.9. Overdose

Overdose of oral or excessive administration of topical xylometazoline hydrochloride may cause severe dizziness, perspiration, severely lowered body temperature, headache, bradycardia, hypertension, respiratory depression, coma and convulsions. Hypertension may be followed by hypotension. Small children are more sensitive to toxicity than adults.

The absorption being very small after nasal or oral administration, an acute overdose after intranasal ipratropium bromide is unlikely but if an overdose occurs the symptoms are dry mouth, accommodation difficulties and tachycardia. The treatment is symptomatic.

A considerable overdose may cause anticholinergic CNS symptoms such as hallucinations, which must be treated with cholinesterase inhibitors.

Appropriate supportive measures should be initiated in all individuals suspected of an overdose, and urgent symptomatic treatment under medical supervision is indicated when warranted. This would include observation of the individual for at least 6 hours. In the event of a severe overdose with cardiac arrest, resuscitation should be continued for at least 1 hour. Further management should be as clinically indicated or as recommended by the national poison centres where available.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

⚠ Not the same combination. This medicine contains Ipratropium bromide, Xylometazoline hydrochloride. The products below do not contain exactly the same set of active substances — they are not direct substitutes.

  • SNUP 0,5 mg/ml over the counter partial — not the same combinationXYLOMETAZOLINUM · eye / ear / nose
  • SNUP 1mg/ml over the counter partial — not the same combinationXYLOMETAZOLINUM · eye / ear / nose
  • VIBROCIL ACTILONG 1 mg/ml over the counter partial — not the same combinationXYLOMETAZOLINUM · eye / ear / nose
  • RHINXYL HA 0,5 mg/ml over the counter partial — not the same combinationXYLOMETAZOLINUM · eye / ear / nose
  • RHINXYL HA 1 mg/ml over the counter partial — not the same combinationXYLOMETAZOLINUM · eye / ear / nose
  • BIXTONIM XYLO 0,5 mg/ml over the counter partial — not the same combinationXYLOMETAZOLINUM · eye / ear / nose

Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • Otrivin Ipra MaxXylometazolini hydrochloridum + Ipratropii bromidum · eye / ear / nose
  • Xedine Ipra MAXXylometazolini hydrochloridum + Ipratropii bromidum · eye / ear / nose

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Otrivine Extra Dual Relief 0.5 mg/ml + 0.6 mg/ml nasal spray, solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →